Table 2.
Clinical studies of NK cell based immunotherapy in the HCC patients
| Interventions | Design | Strategy (brief summary) | Recruitment status | Clinicaltrials.gov identifier |
|---|---|---|---|---|
| “Safety and effectiveness study of autologous natural killer and natural killer t cells on cancer” including HCC | Phase I | NK cell and NKT cell-based autologous adoptive immunotherapy | Suspended | NCT00909558 |
| “Evaluate the efficacy and safety of MG4101 (ex vivo expanded allogeneic NK cell)” | Phase 2 | NK cell transfer after curative liver resection on the patient with advanced HCC | Completed | NCT02008929 |
| By using adoptive transfer of autologous NK cells to prevent recurrence of hepatocellular carcinoma after curative therapy | Phase 2 | Adjuvant adoptive immune therapy using NK cell in patient undergone curative resection (RFA or operation) | Not yet recruiting | NCT02725996 |
| Safety study of NK cells from sibship to treat the recurrence of HCC after liver transplantation | Phase 1 | Conventional treatment and NK cell transfer | Recruiting | NCT02399735 |
| A study of MG4101 (allogeneic natural killer cell) for intermediate-stage of hepatocellular carcinoma | Phase 2 | Allogeneic natural killer cell transfer after transarterial chemoembolization | Recruiting | NCT02854839 |
| Safety study of liver natural killer cell therapy for hepatoma liver transplantation (MIAMINK) | Phase 1 | Liver transplantation and liver NK cell inoculation | Completed | NCT01147380 |
| Recombinant vesicular stomatitis virus expressing IFN-β and probable exertion of anti-tumor activity of NK cells against adult HCC | Phase I | Cytokine therapy | Recruiting | NCT01628640 |